Form 4: Generation Bio Interim CEO's Holdings Post-Merger

Generation Bio Co.'s Interim CEO, Yalonda Howze, reports changes in beneficial ownership following the company's merger with XOMA Royalty Corporation.

Summary

• Yalonda Howze, Interim CEO and President of Generation Bio Co., reported changes in her beneficial ownership of company securities.
• The changes are a direct result of the merger between Generation Bio Co. (the Issuer) and XOMA Royalty Corporation (Parent), which became effective on February 9, 2026.
• Common stock shares of Generation Bio Co. were exchanged for a cash amount of $4.2913 per share and one non-tradeable Contingent Value Right (CVR) per share.
• Each CVR represents the right to receive certain contingent payments in cash, with an estimated maximum contingent consideration amount of $25.01 per CVR.
• Stock options to purchase shares of Common Stock that were outstanding and unexercised immediately prior to the effective time of the merger, and had an exercise price per share equal to or greater than the Cash Amount ($4.2913), were automatically cancelled for no consideration.
• Following the reported transactions, Yalonda Howze beneficially owns 3,759 shares of Common Stock directly and 0 derivative securities.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative event for public shareholders and option holders of Generation Bio Co. due to the cancellation of options for no consideration and the company's delisting, despite the CVRs offering potential future value.

Positives

• Shareholders received a cash payment of $4.2913 per share as part of the merger consideration.
• Shareholders also received a non-tradeable Contingent Value Right (CVR) per share, offering potential future upside with an estimated maximum contingent consideration of $25.01 per CVR.

Negatives

• Stock options with exercise prices equal to or greater than the cash amount ($4.2913) were cancelled for no consideration, resulting in a loss of potential value for option holders.
• Generation Bio Co. is now a wholly-owned subsidiary of XOMA Royalty Corporation, meaning its common stock is no longer publicly traded, effectively delisting the company.

Risks

• The Contingent Value Rights (CVRs) are non-tradeable, which limits liquidity for the contingent payments.
• The contingent payments from the CVRs are subject to specific conditions and are not guaranteed, with an 'estimated maximum' rather than a guaranteed amount, introducing uncertainty regarding their ultimate value.

Future Outlook

Generation Bio Co. is now a wholly-owned subsidiary of XOMA Royalty Corporation, indicating its future operations and strategic direction will be determined by its new parent company. The CVRs offer potential future contingent payments to former shareholders based on specific milestones.

Industry Context

StockSavvy.ai notes that mergers and acquisitions are common in the biotechnology and pharmaceutical sectors, often driven by the desire to consolidate intellectual property, pipelines, or market share. The use of CVRs in such transactions is a mechanism to bridge valuation gaps and share future risks and rewards, particularly for assets with uncertain future milestones or regulatory approvals.

Comparison to Industry Standards

• This transaction structure, involving a cash component and CVRs, is a recognized strategy in biotech M&A. For example, Sanofi's acquisition of Principia Biopharma in 2020 included CVRs tied to the approval of a specific drug.
• Similarly, the acquisition of Acceleron Pharma by Merck in 2021 also featured CVRs, demonstrating a trend where buyers seek to mitigate upfront risk for pipeline assets.
• The $4.2913 cash component, combined with a potential $25.01 CVR, suggests a significant portion of the deal value is tied to future performance, aligning with industry practices for assets with contingent value.

Stakeholder Impact

• Shareholders: Received cash and CVRs for their shares, but lost direct equity ownership in a publicly traded company.
• Option Holders: Those with out-of-the-money options (exercise price equal to or greater than $4.2913) lost their options for no value.
• Employees: The company is now a subsidiary, which could lead to integration changes, though not explicitly stated in this filing.

Next Steps

• Former Generation Bio Co. shareholders will await potential contingent payments from the CVRs based on the terms of the contingent value rights agreement.
• Generation Bio Co. will operate as a wholly-owned subsidiary of XOMA Royalty Corporation, integrating its operations and strategy with its new parent company.

Key Dates

Recommendation

The company's common stock was exchanged as part of a merger, and Generation Bio Co. is now a wholly-owned subsidiary of XOMA Royalty Corporation. This means the stock is no longer publicly traded, and existing shareholders would have tendered their shares. Therefore, a 'sell' recommendation reflects the completion of the transaction for existing holders and the unavailability of the stock for new investment.

Keywords

Generation Bio Co., GBIO, XOMA Royalty Corporation, Merger, Acquisition, Form 4, Beneficial Ownership, Contingent Value Right, CVR, Stock Options, Insider Transaction